Trending Topics

Intravitreal bevacizumab, ranibizumab, or aflibercept for ROP treatment?

A new study compared the efficacy and refractive outcomes of patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab, ranibizumab, and aflibercept. Researchers analyzed data from 187 eyes (111 patients) with ROP, including 54 eyes (30 patients) treated with bevacizumab; 77 eyes (47 patients) treated with ranibizumab; and 56...